CD274 and head and neck squamous cell carcinoma: This emerging PD-1/PD-L1 blockade immunotherapy exhibited more satisfactory curative effects, and lower toxicity for patients with advanced HNSCC compared to standard (Cetuximab + Chemo) treatment [46].